[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432650":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":78,"collaborators":80,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":25,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Angiotensin Receptor Blockers","EXPERIMENTAL","Angiotensin Receptor Blockers will be given orally once a day for 2 years.",[13],"Drug: Angiotensin Receptor Blockers",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive a matched placebo orally once a day for 2 years.",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Angiotensin Receptor Blockers treatment for 2 years.",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo administration for 2 years.",[15],[30],{"name":31,"affiliation":5,"role":32},"Marie-Annick Clavel, PhD","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","418-656-8711","2678","Marie-Annick.Clavel@criucpq.ulaval.ca",[40,60],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"CRIUCPQ","RECRUITING","Québec","Quebec","G1V 4G5","Canada","CA",{"type":49,"coordinates":50},"Point",[51,52],-71.21454,46.81228,{"lat":52,"lon":51},[55,56,58],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},{"name":25,"role":35,"phone":36,"phoneExt":57,"email":25},"3868",{"name":59,"role":35,"phone":25,"phoneExt":25,"email":25},"Marie-Annick Clavel",{"facility":61,"status":42,"city":62,"state":25,"zip":25,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Odense University Hospital","Odense","Denmark","DK",{"type":49,"coordinates":66},[67,68],10.38831,55.39594,{"lat":68,"lon":67},[71,75,77],{"name":72,"role":35,"phone":73,"phoneExt":25,"email":74},"Ali Mulham, MD","+4560677621","Mulham.Ali2@rsyd.dk",{"name":76,"role":35,"phone":25,"phoneExt":25,"email":25},"Jordi Sanchez Dahl, MD, PhD",{"name":72,"role":35,"phone":25,"phoneExt":25,"email":25},{"type":32,"investigatorFullName":59,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Full Professor",[81],{"name":61,"class":6},"100432650","phase-4-angiotensin-receptor-blockers-in-aortic-stenosis-100432650",false,"NCT04913870","Angiotensin Receptor Blockers in Aortic Stenosis","Impact of Angiotensin Receptor Blockers in Aortic Stenosis - a Randomized Controlled Trial","ARBAS","Inclusion Criteria:\n\n* Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \\\u003C4m\u002Fs)\n* Normal left ventricular ejection fraction (i.e. ≥50%)\n* Systolic blood pressure \\>110 mmHg\n* Diastolic blood pressure \\>70 mmHg\n\nExclusion Criteria:\n\n* More than mild aortic or mitral regurgitation, or mitral stenosis\n* Current use or documented indication for renin-angiotensin system medication or Aliskiren\n* Known allergy or intolerance to angiotensin II receptor blockers (ARBs)\n* Alzheimer, dementia or known non-compliant patient\n* Renal dysfunction (glomerular filtration rate \\\u003C30ml\u002Fmin\u002F1.73m2)\n* Chronic hyperkalemia\n* Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment\n* Newly diagnosed (\\\u003C2 months) or poorly controlled diabetes\n* Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (\\\u003C3 months)\n* Pregnant or lactating women\n* Patients unable to read, understand or sign research consent","ALL","20 Years","99 Years",{"count":94,"type":95},144,"ESTIMATED","INTERVENTIONAL",[98],"PHASE4","This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.",[101,102],"Aortic Stenosis","Aortic Valve Stenosis",[104,105,106,107],"Angiotensin II Receptor Blockers","Left ventricular remodeling","Valvular heart disease","Aortic stenosis","2024-12-18",{"date":110,"type":111},"2024-12-20","ACTUAL",{"date":113,"type":111},"2020-02-01",{"date":115,"type":95},"2027-02",{"name":5,"class":6},2]